Customizing competitive strategy to entry timing: Implications for firm performance in the pharmaceutical industry

Julen Castillo‐Apraiz and Jesus Matey

Managerial and Decision Economics, 2020, vol. 41, issue 6, 976-985

Abstract: Our study examines the effect of business‐level strategy on performance. Past literature examining the aforementioned effect in the pharmaceutical industry is scarce. Furthermore, there is a lack of studies that analyze how competitive strategy is contingent on firm entry timing. Hence, to explore our understanding in this area, the present study was conducted in the German pharmaceutical industry. Two hundred valid responses were collected from CEOs. The data were analyzed using SPSS and partial least square (PLS) techniques. The findings indicate a surprising result that, while the differentiation strategy is significantly related to pharmaceutical companies' performance, cost leadership strategy is not.

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://doi.org/10.1002/mde.3152

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:mgtdec:v:41:y:2020:i:6:p:976-985

Access Statistics for this article

Managerial and Decision Economics is currently edited by Antony Dnes

More articles in Managerial and Decision Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().